NASDAQ:AMLX

Amylyx Pharmaceuticals - AMLX News Today

$29.36

+11.46 (+64.02%)

(As of 09/8/2022 10:17 AM ET)

Add

Compare

Today's Range: $28.55
▼
$33.32
50-Day Range: $17.15
▼
$26.99
52-Week Range: $6.51
▼
$33.41

Volume: 276,262 shs
Average Volume: 1.08 million shs
Market Capitalization: $1.72 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.50

Get Amylyx Pharmaceuticals News Delivered to You Automatically

AMLX Media Mentions By Week

AMLX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AMLX
News Sentiment
▼
0.35

0.38
▲
Average
Medical
News Sentiment

AMLX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AMLX Articles
This Week
▼
16

2
▲
AMLX Articles
Average Week

Source

Source	Headline
	Amylyx ALS Drug Wins Backing of FDA Advisory Panel finance.yahoo.com - September 8 at 6:24 AM
	Amylyx Pharma: FDA Advisory Committee Supports Approval Of AMX0035 For Treatment Of ALS markets.businessinsider.com - September 8 at 1:23 AM
	FDA advisers give thumbs-up to ALS drug — with major caveat bizjournals.com - September 7 at 8:22 PM
	Amylyx Pharma wins FDA advisory committee backing for ALS drug seekingalpha.com - September 7 at 8:22 PM
	U.S. FDA panel votes for Amylyx's ALS drug reuters.com - September 7 at 8:22 PM
	UPDATE 2-Amylyx's ALS drug gets U.S. FDA panel's backing in rare turnaround finance.yahoo.com - September 7 at 8:22 PM
	Controversial ALS Drug From Amylyx Gets Rare Second FDA Meeting finance.yahoo.com - September 7 at 8:22 PM
	FDA advisors give thumbs-up to ALS drug — with major caveat finance.yahoo.com - September 7 at 8:22 PM
	Amylyx’s ALS Drug Backed by FDA Advisers finance.yahoo.com - September 7 at 8:22 PM
	Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS finance.yahoo.com - September 7 at 8:22 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	FDA Again Highlights Lacking Data From Amylyx's Amyotrophic Lateral Sclerosis Candidate finance.yahoo.com - September 6 at 6:57 PM
	Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035 finance.yahoo.com - September 2 at 3:17 PM
	The FDA's Mixed Messages Sent Amylyx Pharmaceuticals Stock Off A Cliff finance.yahoo.com - September 2 at 3:17 PM
	These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year finance.yahoo.com - August 29 at 4:10 PM
	Bullish insiders bet US$830k on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) nasdaq.com - August 22 at 9:27 AM
	Amylyx Pharmaceuticals Announces ALBRIOZA™ is Now Available in Canada for the Treatment of ALS finance.yahoo.com - July 29 at 9:53 AM
	Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases finance.yahoo.com - July 18 at 11:52 AM
	Amylyx Pharma: FDA Plans To Reconvene Advisory Committee To Review AMX0035 NDA On Sept. 7 nasdaq.com - July 5 at 5:15 PM
	U.S. FDA to reconvene experts' meeting for Amylyx ALS drug msn.com - July 5 at 5:15 PM
	Amylyx stock rises 8% as FDA panel sets September meeting to discuss ALS drug seekingalpha.com - July 5 at 5:15 PM
	Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022 finance.yahoo.com - July 5 at 5:15 PM
	UPDATE 2-U.S. FDA to reconvene experts' meeting for Amylyx ALS drug finance.yahoo.com - July 5 at 5:15 PM
	Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today finance.yahoo.com - July 5 at 5:15 PM
	Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again finance.yahoo.com - July 5 at 5:15 PM
	Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating finance.yahoo.com - June 28 at 3:22 PM
	Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last seekingalpha.com - June 17 at 4:16 PM
	Amylyx's ALS drug would not be cost effective if priced around $170,000- ICER reuters.com - June 15 at 10:49 AM
	Amylyx Pharma stock adds ~25% a day after Canadian conditional approval for ALS therapy seekingalpha.com - June 14 at 6:51 PM
	Here's How Citi Views Amylyx Pharma finance.yahoo.com - June 14 at 6:51 PM
	Amylyx's ALS drug would be more cost effective if priced around $170,000- ICER finance.yahoo.com - June 14 at 9:34 AM
	Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September markets.businessinsider.com - June 13 at 6:33 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Amylyx wins Canadian approval for ALS therapy under conditions seekingalpha.com - June 13 at 6:33 PM
	Amylyx gets first approval for ALS drug from Canada msn.com - June 13 at 8:59 AM
	Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today benzinga.com - June 3 at 4:11 PM
	Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate markets.businessinsider.com - June 3 at 4:11 PM
	Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today? investorplace.com - June 3 at 12:02 PM
	Amylyx stock rises 16% as FDA extends review period of ALS drug which failed panel backing seekingalpha.com - June 3 at 8:47 AM
	Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS finance.yahoo.com - June 3 at 8:47 AM
	Amylyx says FDA decision date for ALS therapy is now in September; shares jump finance.yahoo.com - June 3 at 8:47 AM
	AMYLYX PHARMACEUTICALS INC finanznachrichten.de - May 26 at 1:40 PM
	Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.19 seekingalpha.com - May 13 at 1:36 AM
	Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results finance.yahoo.com - May 13 at 1:36 AM
	Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS finance.yahoo.com - May 5 at 1:57 PM
	Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting finance.yahoo.com - April 2 at 11:46 AM
	Expert Ratings For Amylyx Pharmaceuticals markets.businessinsider.com - April 1 at 10:36 AM
	Amylyx Slumps as FDA Panel Against OK to Neurodegenerative Drug finance.yahoo.com - March 31 at 7:08 PM
	Amylyx Pharmaceuticals GAAP EPS of -$13.35 beats by $4.80, revenue of $0.28M misses by $0.25M seekingalpha.com - March 31 at 8:49 AM
	FDA Panel Votes Down On Amylyx's ALS Drug, Further Fading Its Hope For Regulatory Success msn.com - March 31 at 8:49 AM
	FDA panel narrowly rejects experimental ALS drug from Amylyx Pharma msn.com - March 31 at 3:49 AM
	FDA Committee Votes Against Amylyx's Amyotrophic Lateral Sclerosis Drug nasdaq.com - March 31 at 3:48 AM

Get Amylyx Pharmaceuticals News Delivered to You Automatically

This page (NASDAQ:AMLX) was last updated on 9/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial Subscription Here

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms